OPtimising Treatment for MIld Systolic hypertension in the Elderly (OPTiMISE):protocol for a randomised controlled non-inferiority trial by Sheppard, James P et al.
                          Sheppard, J. P., Burt, J., Lown, M., Temple, E., Benson, J., Ford, G. A., ...
McManus, R. J. (2018). OPtimising Treatment for MIld Systolic
hypertension in the Elderly (OPTiMISE): protocol for a randomised
controlled non-inferiority trial. BMJ Open, 8(9), [e022930].
https://doi.org/10.1136/bmjopen-2018-022930
Publisher's PDF, also known as Version of record
License (if available):
CC BY
Link to published version (if available):
10.1136/bmjopen-2018-022930
Link to publication record in Explore Bristol Research
PDF-document
This is the final published version of the article (version of record). It first appeared online via BMJ Publishing at
https://bmjopen.bmj.com/content/8/9/e022930 . Please refer to any applicable terms of use of the publisher.
University of Bristol - Explore Bristol Research
General rights
This document is made available in accordance with publisher policies. Please cite only the published
version using the reference above. Full terms of use are available:
http://www.bristol.ac.uk/pure/about/ebr-terms
1Sheppard JP, et al. BMJ Open 2018;8:e022930. doi:10.1136/bmjopen-2018-022930
Open access 
OPtimising Treatment for MIld Systolic 
hypertension in the Elderly 
(OPTiMISE): protocol for a randomised 
controlled non-inferiority trial
James P Sheppard,1 Jenni Burt,2 Mark Lown,3 Eleanor Temple,1 John Benson,4 
Gary A Ford,1 Carl Heneghan,1 F D Richard Hobbs,1 Sue Jowett,5 Paul Little,3 
Jonathan Mant,4 Jill Mollison,1 Alecia Nickless,1 Emma Ogburn,1 Rupert Payne,6 
Marney Williams,7 Ly-Mee Yu,1 Richard J McManus1
To cite: Sheppard JP, Burt J, 
Lown M, et al.  OPtimising 
Treatment for MIld Systolic 
hypertension in the Elderly 
(OPTiMISE): protocol for a 
randomised controlled non-
inferiority trial. BMJ Open 
2018;8:e022930. doi:10.1136/
bmjopen-2018-022930
 ► Prepublication history and 
additional material for this paper 
are available online. To view, 
please visit the journal (http:// 
dx. doi. org/ 10. 1136/ bmjopen- 
2018- 022930).
Received 13 March 2018
Revised 10 August 2018
Accepted 18 August 2018
For numbered affiliations see 
end of article.
Correspondence to
Dr James P Sheppard;  
 james. sheppard@ phc. ox. ac. uk
Protocol
© Author(s) (or their 
employer(s)) 2018. Re-use 
permitted under CC BY. 
Published by BMJ.
AbstrACt
Introduction Recent evidence suggests that larger blood 
pressure reductions and multiple antihypertensive drugs 
may be harmful in older people, particularly frail individuals 
with polypharmacy and multimorbidity. However, 
there is a lack of evidence to support deprescribing of 
antihypertensives, which limits the practice of medication 
reduction in routine clinical care. The aim of this trial is to 
examine whether antihypertensive medication reduction 
is possible in older patients without significant changes in 
blood pressure control at follow-up.
Methods and analysis This trial will use a primary care-
based, open-label, randomised controlled trial design. A 
total of 540 participants will be recruited, aged ≥80 years, 
with systolic blood pressure <150 mm Hg and receiving 
≥2 antihypertensive medications. Participants will have 
no compelling indication for medication continuation and 
will be considered to potentially benefit from medication 
reduction due to existing polypharmacy, comorbidity and 
frailty. Following a baseline appointment, individuals will 
be randomised to a strategy of medication reduction 
(intervention) with optional self-monitoring or usual 
care (control). Those in the intervention group will have 
one antihypertensive medication stopped. The primary 
outcome will be to determine if a reduction in medication 
can achieve a proportion of participants with clinically 
safe blood pressure levels at 12-week follow-up (defined 
as a systolic blood pressure <150 mm Hg), which is non-
inferior (within 10%) to that achieved by the usual care 
group. Qualitative interviews will be used to understand 
the barriers and facilitators to medication reduction. The 
study will use economic modelling to predict the long-term 
effects of any observed changes in blood pressure and 
quality of life.
Ethics and dissemination The protocol, informed 
consent form, participant information sheet and all other 
participant facing material have been approved by the 
Research Ethics Committee (South Central—Oxford A; 
ref 16/SC/0628), Medicines and Healthcare products 
Regulatory Agency (ref 21584/0371/001–0001), host 
institution(s) and Health Research Authority. All research 
outputs will be published in peer-reviewed journals and 
presented at national and international conferences.
trial registration number EudraCT 2016-004236-38; 
ISRCTN97503221; Pre-results.
IntroduCtIon 
The general population is ageing1 and, conse-
quently, the number of people living with 
age-related chronic conditions is increasing.2 
Hypertension is the number one comorbid 
condition in older people with multiple chronic 
conditions3 and 52% of those aged ≥80 years 
are prescribed two or more antihypertensive 
drugs (equivalent to approximately 1.25 million 
people in the UK).4 Blood pressure lowering 
has been shown to be effective at preventing 
stroke and cardiovascular disease in healthy 
individuals aged ≥80 years with stage 2 hyper-
tension (systolic blood pressure of >160 mm 
Hg) and high-risk stage 1 hypertension.5 6 
However, as with many trials,7 8 these studies 
included healthier populations with lower 
polypharmacy and multimorbidity than might 
be expected in the general elderly population. 
strengths and limitations of this study
 ► This will be the first UK randomised controlled trial to 
compare a strategy of antihypertensive medication 
reduction with usual care in primary care.
 ► The pragmatic trial design, with broad inclusion cri-
teria, will make findings of the study externally valid 
in routine clinical practice.
 ► Allowing the attending general practitioner to choose 
the medication to be reduced will maximise external 
validity of the trial results, but precludes the possi-
bility of blinding the participants and investigators.
 ► The trial will be powered to detect a non-inferior dif-
ference in blood pressure control at follow-up, but 
not necessarily secondary outcomes such as differ-
ences in rates of cardiovascular disease, adverse 
events and quality of life.
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In addition, there is evidence to suggest that larger blood 
pressure reductions and multiple antihypertensive prescrip-
tions may be harmful in older people.9 10 Evidence from 
observational studies also suggests that higher intensity 
blood pressure treatment is associated with increased risk 
of falls in older people,11 although this is also disputed.5 
Some patients consider the increased risk of falls and 
other adverse events (AEs) to be as important as the risk of 
myocardial infarction or stroke, particularly those taking 
medications for primary prevention of cardiovascular 
disease.12 Thus, decisions over blood pressure lowering 
in the elderly, particularly the frail elderly, require the 
weighing of harms and quality of life. However, clinicians 
can often struggle to stop prescribing medication due to 
a perceived lack of evidence, fear of the reaction of other 
prescribers, fear of precipitating events such as stroke or 
angina and concern that patients will feel their care is 
being cut.13 14
There is limited evidence from randomised trials exam-
ining the safety of antihypertensive medication reduction 
or withdrawal.15–19 The Hypertension in the Very Elderly 
Trial (HYVET)5 enrolled some patients on antihyperten-
sive treatment who were then randomised to placebo 
(effectively complete medication withdrawal) and the 
second Australian National Blood Pressure trial inves-
tigators followed up participants who withdrew medi-
cation during the trial run-in period but who were not 
randomised into the trial. They found younger patients 
with lower baseline blood pressure and fewer drug 
prescriptions were more likely to sustain medication with-
drawal at 12-month follow-up.20 21 However, there are few 
trials comparing a specified strategy of antihypertensive 
medication reduction with usual care in terms of effects 
on blood pressure control and quality of life.17 In addi-
tion, there are no previous economic modelling studies 
of a strategy of medication reduction in the elderly.
The aim of this work will be to examine whether anti-
hypertensive medication reduction in patients with 
controlled systolic hypertension (≤150 mm Hg) who 
are being prescribed two or more antihypertensives is 
possible without significant changes in blood pressure 
control at follow-up.
MEthods
Aims and outcomes
The aim of this study is to determine whether antihyper-
tensive medications can be safely reduced without systolic 
blood pressure increasing beyond what is clinical accept-
able at follow-up.
The primary outcome is the proportion of participants 
with clinically acceptable blood pressure levels at 12-week 
follow-up (defined as a systolic blood pressure <150 mm 
Hg). Secondary outcomes will examine:
 ► The proportion of participants in the intervention 
arm who maintain medication reduction through to 
follow-up (ie, are not restarted on therapy).
 ► The difference in quality of life (according to 
EQ-5D-5L) between groups at 12-week follow-up.
 ► The difference in frailty (according to the frailty 
index)22 between the two groups at 12-week follow-up.
 ► The difference in the change in mean clinic systolic 
blood pressure (from baseline) between the two 
groups at 12-week follow-up.
 ► The difference in reported side effects to medica-
tion between the two groups at 12-week follow-up 
(including coughs, dizziness, syncope, and ankle 
swelling).
 ► The difference in routinely reported serious adverse 
events (SAEs) between the two groups at 12-week 
follow-up (hospitalisation due to falls, myocardial 
infarction, stroke or all-cause mortality).
design
This trial will use a primary care-based, open-label, 
randomised controlled, two-parallel groups, non-in-
feriority trial design, recruiting 540 participants with 
controlled blood pressure (systolic <150 mm Hg) on two 
or more antihypertensive treatments. Participants will be 
randomised to a strategy of medication reduction (inter-
vention) or usual care (control) and followed-up for 12 
weeks (figure 1). Embedded qualitative and economic 
analyses will examine barriers and facilitators to medica-
tion reduction and the cost-effectiveness of the approach.
trial participants
Patients eligible for the trial will be aged ≥80 years, with 
systolic blood pressure <150 mm Hg (current UK guide-
line recommendation)23 receiving ≥2 antihypertensive 
medications. They will have no compelling indication 
for medication continuation and in the opinion of the 
attending GP, may potentially benefit from medication 
reduction due to existing polypharmacy, comorbidity 
and/or frailty (box 1).
Participants will be identified and recruited from general 
practices via the UK Clinical Research Network. Potentially 
eligible patients will be identified by trained practice staff 
searching practice-based electronic disease registers using 
a standardised strategy. GPs will be asked to check the 
search results and remove people whom they believe to be 
unsuitable to participate in the study. Remaining potentially 
eligible patients will be sent letters of invitation from their 
GP and those expressing an interest in the trial will be asked 
to attend a screening and baseline appointment. Patients not 
responding to the first invitation will receive one reminder 
letter (up to 4 weeks after the first letter). Other potentially 
eligible patients may also be approached opportunistically 
by a member of the clinical care team. Those who do not 
wish to take part will be asked to fill in a short questionnaire 
detailing their reasons.
baseline visit
Eligible patients will have informed consent taken by the 
GP. During the consent appointment, the GP will show a 
2 min study video infographic (see online supplementary 
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material) and go through the participant information 
sheet explaining the exact nature of the trial. Having had 
a chance to ask questions, those individuals willing to 
participate will give written informed consent by means of 
a participant dated signature and dated signature of the 
GP who presented and obtained the informed consent.
Some participants will be invited to have their inter-
view audio-recorded for qualitative analysis during their 
study visits. Those who are interested will be asked to 
sign a response slip prior to meeting the GP. Consent to 
audio-recordings will not have a bearing on an individu-
al’s care or eligibility for the main trial.
Those giving informed consent will be screened using the 
criteria in box 1 and undergo baseline measurements and 
randomisation by a member of the research team via partic-
ipant questionnaires and a detailed notes review (table 1).
Figure 1 Trial flow diagram. *Monitoring of blood pressure at home will be encouraged but those not willing or able will 
still be included in the trial. All participants will be asked to attend a safety monitoring visit with their GP/nurse 4 weeks 
after baseline. GP, general practitioner; BP, blood pressure; HDL, high-density lipoprotein; ICD, International Statistical 
Classification of Diseases and Related Health Problems; CVD, cardiovascular disease; eGFR, estimated glomerular filtration rate; 
MARS, Medication Adherence Rating Scale; MOCA, Montreal Cognitive Assessment.
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Blood pressure will be measured in a standardised 
fashion using the clinically validated24 BpTRU blood 
pressure monitor, which automatically records six blood 
pressure measurements at 1 min intervals. Blood pres-
sure readings will be taken in the left arm (where appro-
priate) after participants have been seated for at least 
5 min of rest, using an appropriate sized cuff. The mean 
of the second and third readings will be used to define 
the primary outcome. To test for orthostatic hypotension, 
two further readings will be taken in the standing position 
after 1 and 3 min.25 Only the research facilitator/nurse 
will be present during the blood pressure measurements. 
Orthostatic hypotension will be defined as a >20 mm Hg 
drop in systolic blood pressure within 3 min of standing.
All data will be collected via an electronic case report 
form (eCRF) linked to the study database. Participants 
will be given the option to enter responses to question-
naires themselves or with assistance from the research 
team. Where questionnaires are not validated for use on 
a tablet computer,26 or where individuals are not comfort-
able using one, paper copies will be made available for 
completion.
randomisation
Consenting participants will be individually randomised 
(1:1 allocation ratio) to one of two study arms using a fully 
validated web-based system (Sortition) with manual tele-
phone back up. Participants will not be randomised until 
after consent has been taken and baseline assessments 
have been completed. A computer-generated non-deter-
ministic algorithm, minimising on practice and baseline 
systolic blood pressure will be used to ensure these covari-
ates are balanced between the two intervention arms.
The study will use an open-label design, so patients and 
practitioners will not be blinded to the intervention or 
study end points. Therefore, codebreaking will not be 
necessary. The statistical analysis will be performed blind 
to patient allocation.
Intervention group
Participating GPs will review each participant’s antihy-
pertensive medication regimen prior to the baseline 
appointment, and decide which medication should 
be removed if they are randomised to the interven-
tion arm of the trial. The choice of medication to be 
withdrawn will be at the discretion of the GP, but their 
decision will be informed by an individual’s comor-
bidities and existing guidelines, where appropriate 
(figure 2). Specifically, participating GPs will be encour-
aged to identify previously unrecognised contraindi-
cations to medication, defined by the Screening Tool 
of Older Person's Prescriptions (STOPP) criteria.27 In 
the absence of these, or a strong clinical rationale for 
continuing despite a STOPP criteria being met, GPs will 
be recommended to reduce antihypertensive medica-
tions in reverse of the National Institute for Health and 
Care Excellence C+A+D algorithm for older patients 
(figure 2).23 All participants in the trial will remain on at 
least one antihypertensive.
Once a medication has been removed, GPs or other 
appropriate, delegated healthcare professionals will 
closely monitor the participant’s response to medication 
reduction: they will be given advice about what and when 
to monitor (figure 3), but this schedule will be flexible. 
All participants will be expected to return for at least one 
routine safety follow-up visit, and further visits may be 
required if blood pressure is raised (≥150 mm Hg), or AEs 
occur. Where blood pressure is persistently raised, GPs 
will be expected to re-adjust medication (dose or type), 
rendering the likelihood of an SAE occurring as a result 
of the intervention very low.
box 1 trial inclusion and exclusion criteria
Inclusion criteria
 ► Participant is willing and able to give informed consent for partici-
pation in the trial.
 ► Male or female, aged 80 years or above.
 ► Clinic systolic blood pressure <150 mm Hg (according to screen-
ing measurement at baseline—clinic blood pressure defined as the 
mean of the second and third readings taken at 1 min intervals).
 ► Prescribed two or more antihypertensive medications to lower blood 
pressure for at least 12 months prior to trial entry. Antihypertensive 
medications defined as any ACE inhibitor, angiotensin II receptor 
blocker, calcium channel blocker, thiazide and thiazide-like diuretic, 
potassium-sparing diuretic, alpha-blocker, beta-blocker, vasodilator 
antihypertensives, centrally acting antihypertensives, direct renin 
inhibitors, adrenergic neuron blocking drugs or loop diuretics.
 ► Stable dose of antihypertensive medications for at least 4 weeks 
prior to trial entry.
 ► In the investigator’s opinion, could potentially benefit from medica-
tion reduction due to existing polypharmacy, comorbidity, non-ad-
herence or dislike of medicines and/or frailty.
 ► In the investigator’s opinion, is able and willing to comply with all 
trial requirements.
Exclusion criteria
 ► A participant has heart failure due to LVSD and is on only ACE in-
hibitors/ARBs and/or beta-blockers and/or spironolactone (removing 
any of which would be contraindicated).
 ► A participant has heart failure but has not had an echocardiogram 
since its onset (might have undiagnosed LVSD and a compelling 
need for ACE inhibitors/ARB and beta-blockers).
 ► Investigator deems that there is a compelling indication for antihy-
pertensive medication continuation.
 ► Any other significant disease or disorder which, in the opinion of 
the investigator, may either put the participants at risk because of 
participation in the trial, or may influence the result of the trial, or 
the participant’s ability to participate in the trial (eg, terminal illness, 
house bound and unable to attend baseline and follow-up clinics).
 ► Suffered a myocardial infarction or stroke within the past 12 months.
 ► Blood pressure being managed outside of primary care.
 ► Unable to provide consent due to incapacity.
 ► A participant with secondary hypertension or previous accelerated 
or malignant hypertension.
 ► Participants who have participated in another research trial involv-
ing antihypertensive medication in the past 4 weeks.
ARB, angiotensin II receptor blocker; LVSD, left ventricular systolic dysfunction.
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self-monitoring
All participants randomised to the medication reduc-
tion arm of the trial will be given the option to self-mon-
itor their blood pressure at home. Those accepting will 
be trained using protocols developed in the previous 
TASMIN trials28 29 and will be given simple and clear 
instructions to contact their GP if their blood pressure 
rises above what is considered clinically safe (eg, home 
systolic blood pressure >145 mm Hg on all readings taken 
in a week). Participants will be advised to self-monitor (or 
have a carer monitor) at least four times per week in the 
last week of each month of follow-up (weeks 4, 8 and 12), 
although they can monitor more frequently if they wish. 
Differential use of self-monitoring in the intervention 
group, or indeed in the control group (many patients 
now self-monitor routinely)30 is not expected to impact 
on the study results, since there is good evidence that 
self-monitoring only affects blood pressure levels if used 
in combination with a co-intervention.31 All other clinical 
care will continue as usual.
Control group
Those allocated to the control arm of the study will 
continue usual clinical care (ie, they will continue to take 
Table 1 Variables and schedule of data collection
No. Variable
Data source Schedule
Medical 
notes
Measured/
collected at clinic Baseline Follow-up
1 Age ✓ ✓ 
2 Sex ✓ ✓ 
3 Ethnicity ✓ ✓ 
4 Marital status ✓ ✓ 
5 Education ✓ ✓ 
6 Duration of hypertension ✓ ✓ 
7 Past medical history ✓ ✓ 
8 Alcohol consumption ✓ ✓ ✓ 
9 Smoking ✓ ✓ ✓ 
10 Height ✓ ✓ ✓ 
11 Weight ✓ ✓ ✓ 
12 Clinic blood pressure (sitting and standing) ✓ ✓ ✓ 
13 Cholesterol (total and HDL) ✓ ✓ 
14 Estimated glomerular filtration rate ✓ ✓ 
15 Prescribed or over-the-counter medications (all 
medications)*
✓ ✓ ✓ ✓ 
16 Quality of life (according to EQ-5D-5L)26 ✓ ✓ ✓ 
17 Functional independence (defined by modified Rankin 
Scale)38
✓ ✓ 
18 Frailty (according to the FRAIL scale)39 ✓ ✓ ✓ 
19 Frailty (according to the frailty index and electronic 
frailty index)22 40
✓ ✓ ✓ ✓ 
20 Cognitive function (defined by the Montreal Cognitive 
Assessment)41
✓ ✓ 
21 Adherence to medication (according to the Medication 
Adherence Rating Scale Questionnaire)42
✓ ✓ ✓ 
22 Adherence to medication reduction ✓ ✓ 
23 ICD-10 coded cardiovascular events and mortality 
during the trial
✓ ✓ 
24 Recording of potential side effects to medication ✓ ✓ ✓ 
25 Recording of adverse events ✓ ✓ ✓ 
*Drug substance/name, formulation, dose, frequency, start date and adherence over past 12 months (according to clinical system).
HDL, high-density lipoprotein; ICD, International Statistical Classification of Diseases and Related Health Problems.
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antihypertensive medications as prescribed and will not 
self-monitor unless already doing so). No other medica-
tion changes will be mandated and participating GPs will 
be asked to manage all other care according to usual clin-
ical practice.
Follow-up visits
Participants will attend one research follow-up clinic, 12 
weeks (±2 weeks) after baseline and those in the interven-
tion will attend one additional safety visit after 4 weeks (±2 
weeks) (figure 1). A period of 4 weeks is expected to be 
sufficiently long enough to assess the impact of antihyper-
tensive medication reduction, since these drugs usually 
take approximately 4 weeks to ‘wash out’ of a patient’s 
system. Earlier safety visits are not recommended since 
they could provide false reassurance that blood pressure 
is within safe limits if the withdrawn drug has not washed 
out of the participant’s system.
The follow-up assessments will include standardised 
blood pressure measurement (for assessment of the 
primary outcome), questionnaire assessments and adher-
ence to the trial medication regime, side effects and AEs 
(table 1). Where possible, all participants will be flagged 
for mortality and hospital admissions using National 
Health Service patient tracking services, permitting long-
term follow-up for up to 5 years after the trial has finished.
Each participant has the right to withdraw from the 
trial at any time. We will ask all participants to attend 
a follow-up visit as far as is practicable, regardless of 
whether medication is re-introduced to participants in 
the intervention group, or a participant in the control 
group has medication withdrawn. Unless a participant 
withdraws consent, vital status will be assessed even where 
an individual has been lost to follow-up (eg, moved away). 
If given, the reason for withdrawal will be recorded in the 
eCRF.
Internal feasibility study
A two-stage internal feasibility study will be conducted 
to examine methods of patient invitation and rates of 
recruitment, before proceeding with the main trial. The 
first feasibility phase will last for a minimum of 3 months 
and aim to recruit approximately 25 participants from a 
minimum of 3–5 practices. The aim will be to establish 
whether or not anyone will be willing to participate in the 
study.
Figure 2 Medication reduction algorithm. Screening Tool of Older Person's Prescriptions (STOPP) criteria withdraw one of 
the following medications if any of the ensuing contraindications are identified: thiazide diuretic with a history of gout (may 
exacerbate gout), beta-blocker in combination with verapamil (risk of symptomatic heart block), non-cardioselective beta-
blocker with chronic obstructive pulmonary disease (risk of bronchospasm), calcium channel blockers with chronic constipation 
(may exacerbate constipation), use of diltiazem or verapamil with New York Heart Association class III or IV heart failure (may 
worsen heart failure). GP, general practitioner; NICE, National Institute for Health and Care Excellence. 
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The second feasibility phase will focus on recruitment 
rates for the main trial and whether the intended sample 
size is likely to be met during the recruitment period. This 
phase will have a recruitment target of 75 participants 
from 10 practices over 6 months, giving a total sample 
for the feasibility study of 100 participants. A recruitment 
rate of 15% of invitations sent is expected. The following 
actions will be considered to address varying rates of 
recruitment at the end of the feasibility phases:
 ► If ≥100 participants are recruited, trial will proceed as 
planned.
 ► If 75–99 participants are recruited, recruitment mate-
rials/method will be re-examined and edited where 
necessary following discussions with stakeholders and 
patient and public involvement representatives.
 ► If 50–74 participants are recruited, the allocation of 
resources and recruitment criteria will be re-examined 
using information gathered from concurrent qualita-
tive work.
 ► If <50 participants are recruited, the Trial Steering 
Committee (TSC) will decide, in discussion with the 
Data Monitoring and Ethics Committee (DMEC) and 
the funders, whether the trial should be stopped due 
to futility.
sample size calculation
Assuming that 100% of participants in the usual care 
group, and 96% of those in the medication reduction 
group have controlled systolic blood pressure levels 
(<150 mm Hg) at follow-up, approximately 540 partici-
pants will be required to detect a non-inferior difference 
in systolic blood pressure control between groups. Calcu-
lations assume a 10% non-inferiority margin, 90% power, 
2.5% one-sided level of significance, 10% loss to follow-up 
Figure 3 Postmedication reduction monitoring flow chart. The full effects of most oral antihypertensives can last for up to 
4–6 weeks. Frequent monitoring in the initial 4 weeks after drug withdrawal is thus not required unless blood pressure (BP) levels 
are extreme or there are other clinical concerns (see above). Where systolic/diastolic BP values fall into different categories, 
consider the higher value. BP should be taken as the averaged second and third measurements using a validated monitor. 
Standard clinical care/monitoring should align with the National Institute for Health and Care Excellence recommendations.23
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and a 10% dilution effect due to cross-over between 
arms. There is no existing precedent for an appropriate 
margin of non-inferiority in this type of trial, but 10% was 
deemed useful to inform future doctor-patient discus-
sions about medication reduction: if the non-inferiority 
margin is met, it will suggest that for every 10 patients who 
have their medication reduced, at least 9 will still have 
controlled blood pressure at 12-week follow-up.
statistical analysis
A detailed statistical analysis plan will be agreed prior to 
the end of the trial. The primary and secondary analyses 
will be by intention to treat (ITT), unless stated other-
wise. The primary analysis will be a non-inferiority anal-
ysis by means of the ‘two one-sided test’ procedure,32 
whereby the 95% CI for the relative risk of participants 
with systolic blood pressure at 12 weeks below 150 mm Hg 
between the medication reduction group and the usual 
care group is calculated. This will be obtained by means 
of a generalised linear mixed effects model with GP 
surgery included as a random effect and baseline blood 
pressure as a fixed effect. If the lower limit of the CI is 
>0.9 (equal to a risk difference of 10%) then the research 
hypothesis that medication reduction will be non-inferior 
in terms of blood pressure control to usual care will be 
accepted. As a secondary analysis of the primary outcome, 
a per-protocol (PP) analysis will be performed, since ITT 
can be anticonservative for a non-inferiority hypothesis.32 
Participants who received the medication reduction inter-
vention in the PP analysis will be defined as a participant 
in the medication reduction arm who maintained their 
medication reduction throughout the 12-week follow-up 
period.
Secondary analyses will examine the proportion of 
participants in the medication reduction arm who 
maintained their medication reduction throughout 
the 12-week follow-up period. Secondary outcomes will 
be analysed by means of linear mixed effects models, 
adjusting for the baseline level of the outcome and base-
line systolic blood pressure and including practice as a 
random effect: systolic blood pressure, EQ-5D-5L and the 
Frailty index/frail scale. The difference in the rate of side 
effects and AEs between the medication reduction and 
usual care arms will be analysed by means of a logistic 
mixed effects model adjusting for baseline systolic blood 
pressure and including practice as a random effect.
Exploratory subgroup analyses of blood pressure 
control, change in blood pressure and maintenance of 
medication reduction will be conducted by different 
levels of baseline frailty, functional independence, cogni-
tive function, number of medications prescribed at base-
line and number of comorbidities at baseline.
Patient and public involvement
This protocol was developed through discussions with 
older patients and carers and members of an AgeUK 
day centre. MW is a stroke survivor with experience as a 
volunteer on the elderly ward of Charing Cross Hospital. 
She was consulted on the suitability and design of the 
trial and is a member of the trial management group. 
Methods of patient approach, including the design of the 
video infographic, patient information sheet and consent 
form were all reviewed by patient representatives prior 
to formal approval. The TSC includes two independent 
patient representatives responsible for overseeing the 
conduct of the trial.
safety reporting
AEs that are observed by an investigator or reported by 
the participant will be recorded on the AE log at any time 
during the study but AEs will be specifically asked about 
at the 12-week follow-up. SAEs will be reported to the 
coordinating centre within 24 hours of discovery or notifi-
cation of the event. All SAE reports will be reviewed by the 
DMEC chair on a monthly basis, and by the full DMEC at 
meetings held every 6 months. The DMEC will include a 
geriatrician, statistician and consultant clinical pharma-
cologist. They will be responsible for safeguarding trial 
participants, monitoring emerging trial data including 
identifying any trends, such as increases in unexpected 
events, and take appropriate action where necessary.
All AEs labelled possibly, probably or definitely related 
will be considered as related to the intervention. Since 
there are no sections of the Summary of medicinal 
Product Characteristics, or previous clinical studies which 
detail expected AEs as a result of medication withdrawal, 
all SAEs at least possibly related, and not as a result of 
re-introduction of withdrawn medication, will be consid-
ered unexpected and reported as Suspected Unexpected 
Serious Adverse Reaction (SUSARs). Fatal and life-threat-
ening SUSARs will be reported by the chief investigator 
to the relevant Competent Authority and Research 
Ethics Committee no later than 7 calendar days after the 
sponsor or delegate is first aware of the reaction. All other 
SUSARs will be reported within 15 calendar days.
Qualitative substudies
Study 1: interviews with doctors and patients
Face-to-face interviews with GPs and patients will be 
conducted to generate understanding about the barriers 
and facilitators to antihypertensive medication reduction. 
Informed consent will be sought from approximately 15 
GPs to provide a broad range of opinion from varying 
practice sizes (small to large) and settings (rural to 
urban). Participating GPs will also be asked to identify up 
to 15 patients for interview, based on the same inclusion 
criteria as those applied to participants in the main trial.
Interviews with GPs will use a chart-stimulated recall 
approach to explore the factors which influence their 
treatment choices in older hypertensive patients. Anony-
mised electronic health records will be used to focus 
discussions about how GPs would feel about reducing 
antihypertensive medications. Interviews with patients 
will use ‘brown bag’ medication review techniques33 
to create a complete record of medication held, with a 
commentary on usage from the participants’ perspective. 
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Diagrammatic elicitation techniques will be used to 
complete a relational map outlining participants’ 
circumstances and how these relate to the medications 
taken. These sketches will be used as the basis for a 
discussion on the implications of withdrawing antihyper-
tensive medications, and what this ‘gap’ might mean for 
the patient.
All interviews will be transcribed verbatim, stored and 
organised using NVivo software (QSR International, 
Doncaster, Victoria, Australia). Interview and visual 
data from GP and patient interviews will be subjected 
to thematic analysis, with a particular orientation to 
exploring clinical and patient perspectives on the barriers 
and facilitators to reducing antihypertensives.
Study 2: assessment of trial recruitment and data collection 
procedures
The aim of the second qualitative study will be to explore 
how information is presented within recruitment appoint-
ments and how this might impact on consent to partici-
pate, with a view to ensuring robust trial procedures using 
an iterative process. This will be achieved by audio-re-
cording (with consent) up to 75 consultations between 
GPs or research assistants and eligible patients.
Thematic analysis will be undertaken on a sample of 
around 15–20 consultations comprising patients who 
did, or did not consent to participate, to consider (a) 
terminology used, (b) presentation of the deprescribing 
approach and (c) presentation of randomisation. 
This will inform ongoing trial procedures and future 
implementation.
Economic substudy
This work will adapt a previous decision-analytic model 
examining the long-term costs and benefits from blood 
pressure-lowering treatment34 to include potential harms 
of treatment. The model will be adjusted for the effects 
of blood pressure lowering on cardiovascular disease risk, 
costs and quality-adjusted life-years (QALYs) to match the 
older population involved in this work. Costs of the ther-
apies prescribed, side effects and acute and long-term 
costs of cardiovascular events will be obtained within the 
trial and from the literature. Quality of life on each treat-
ment strategy will be obtained from the trial data using 
EQ-5D-5L, and previous studies will inform utility values 
for cardiovascular disease health states and the impact of 
side effects. The model will determine the cost per addi-
tional QALY gained of the medication reduction inter-
vention versus usual care and analyses will be conducted 
from a health and social services perspective. The model 
will be run with a lifetime perspective, with costs and bene-
fits discounted at a rate of 3.5%. A value of information 
analysis will assess whether a further trial would be appro-
priate to reduce decision uncertainty, and identify those 
parameters where more precise estimates would be most 
valuable and should therefore be chosen as outcomes for 
such a trial.
Ethics and dissemination
This research involves older participants, some of whom 
may be considered vulnerable. Great care will be taken 
to ensure all potential participants have the trial clearly 
explained, and are given sufficient time to decide whether 
to give informed consent. This will include provision of 
simplified, participant information sheets with large fonts, 
video infographics to explain the study and extended GP 
consultation periods for explaining the study and taking 
informed consent. The study sponsor has reviewed the 
study proceedures and ensured all indemnity and insur-
ance requirements for the trial were in place prior to the 
start of recruitment.
All research outputs from this work will be published 
in peer-reviewed journals, presented at scientific confer-
ences and lay and social media (eg, Twitter, blogs). 
‘Patient friendly’ study summary documents and info-
graphics will be made available to all participants at the 
end of the trial via the study website.
Current trial status
The trial commenced recruitment on 10 April 2017 and is 
estimated to continue recruitment until September 2018.
dIsCussIon
Current guidelines in the UK suggest that doctors should 
ensure that patients are fully informed of the benefits and 
risks of their prescribed medications and where appro-
priate, discuss the potential for medication withdrawal 
in frail individuals with multimorbidity.35 This is difficult 
given consultation time constraints and fear that depre-
scribing might result in harm.36 This is compounded by 
conflicting and inconclusive evidence about the benefits 
and harms of treatment, and a lack of evidence about 
what will happen if these treatments are reduced.
The ECSTATIC trial enrolled 1067 younger partic-
ipants aged 40–70 years, taking antihypertensives for 
primary prevention of cardiovascular disease.18 The trial 
demonstrated that only 27% of participants were able 
to maintain medication reduction throughout follow-up 
and at 3 months, systolic blood pressure was on average 
6 mm Hg higher in the deprescribing group. At 2-year 
follow-up, the risk of uncontrolled blood pressure was 
significantly higher in those patients attempting to depre-
scribe. Unlike the present study, the medication reduc-
tion algorithm used did not encourage reintroduction of 
therapy if blood pressure was persistently raised.
The Discontinuation of Antihypertensive Treatment in 
Elderly people (DANTE) study16 examined the effect of 
complete antihypertensive medication discontinuation in 
385 patients over the age of 75 years and with mild cogni-
tive deficits. After 16 weeks of follow-up, they observed a 
7/3 mm Hg increase in blood pressure but no difference 
in overall cognition compound score or quality of life 
between groups. A study by van der Wardt et al19 exam-
ined the feasibility of a trial reducing antihypertensives 
in patients with dementia, but was only able to recruit 
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nine participants for the withdrawal programme (1% 
recruitment rate) and a larger trial was deemed unfea-
sible. Similarly, the Opti-Med trial37 demonstrated in 95 
participants that a broader deprescribing approach is 
achievable in patients living in nursing homes, but was 
unable to examine the effect on clinical outcomes due to 
recruitment issues resulting in only 38% of the planned 
sample size being enrolled.
The OPtimising Treatment for MIld Systolic hyperten-
sion in the Elderly (OPTiMISE) trial will target frail indi-
viduals with polypharmacy and comorbidity, and aim to 
establish whether a strategy of antihypertensive medica-
tion reduction is safe and acceptable to older patients. 
The findings of this trial will support better patient-cen-
tred management plans for the prevention of cardio-
vascular disease in older individuals and inform future 
deprescribing trials in primary care.
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